ECSP066303A - Uso de antagonistas del receptor de angiotensina ii - Google Patents

Uso de antagonistas del receptor de angiotensina ii

Info

Publication number
ECSP066303A
ECSP066303A EC2006006303A ECSP066303A ECSP066303A EC SP066303 A ECSP066303 A EC SP066303A EC 2006006303 A EC2006006303 A EC 2006006303A EC SP066303 A ECSP066303 A EC SP066303A EC SP066303 A ECSP066303 A EC SP066303A
Authority
EC
Ecuador
Prior art keywords
ppargamma
angiotensin
inhibitor
telmisartan
activity
Prior art date
Application number
EC2006006303A
Other languages
English (en)
Inventor
Michael Mark
Stefan Kauschke
Ulrich Kintshcer
Michael Schupp
Thomas Unger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34119379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP066303A publication Critical patent/ECSP066303A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere al uso de antagonistas del receptor de la angiotensina II para el tratamiento de personas en las que se diagnosticó diabetes mellitus de tipo 2 o existe sospecha de una prediabetes, para la prevención de diabetes o para el tratamiento del síndrome metabólico y la resistencia a la insulina en pacientes con presión arterial normal.
EC2006006303A 2003-07-31 2006-01-23 Uso de antagonistas del receptor de angiotensina ii ECSP066303A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10335027A DE10335027A1 (de) 2003-07-31 2003-07-31 Verwendung von Angiotensin II Rezeptor Antagonisten
DE10346260A DE10346260A1 (de) 2003-07-31 2003-10-06 Verwendung von Angiotensin II Rezeptor Antagonisten
DE10356815A DE10356815A1 (de) 2003-07-31 2003-12-05 Verwendung von Angiotensin II Rezeptor Antagonisten

Publications (1)

Publication Number Publication Date
ECSP066303A true ECSP066303A (es) 2006-10-25

Family

ID=34119379

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006303A ECSP066303A (es) 2003-07-31 2006-01-23 Uso de antagonistas del receptor de angiotensina ii

Country Status (28)

Country Link
US (1) US20050070594A1 (es)
EP (3) EP1651213B2 (es)
JP (1) JP4833840B2 (es)
KR (1) KR20060054404A (es)
CN (3) CN1829511B (es)
AT (1) ATE443519T1 (es)
AU (1) AU2004260606B2 (es)
BR (1) BRPI0413165A (es)
CA (1) CA2534006C (es)
CY (1) CY1109560T1 (es)
DE (4) DE10335027A1 (es)
DK (2) DK1651213T4 (es)
EA (2) EA017640B1 (es)
EC (1) ECSP066303A (es)
ES (2) ES2334136T5 (es)
HU (1) HUE027274T2 (es)
IL (1) IL172693A (es)
ME (1) MEP51108A (es)
MX (1) MXPA06001322A (es)
NO (1) NO335444B1 (es)
NZ (1) NZ544877A (es)
PL (2) PL2119441T3 (es)
PT (1) PT1651213E (es)
RS (1) RS50793B (es)
SI (1) SI1651213T2 (es)
UA (1) UA83854C2 (es)
WO (1) WO2005011680A1 (es)
ZA (1) ZA200509835B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
RS53141B (sr) * 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
CN1298389C (zh) * 2005-01-18 2007-02-07 广东省人民医院 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20090156579A1 (en) * 2005-10-25 2009-06-18 Hasegawa Philip A Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension
RU2308947C1 (ru) * 2006-02-26 2007-10-27 Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН) Лекарственное средство с гиполипидемическим эффектом "симваглизин"
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101260103A (zh) * 2007-03-09 2008-09-10 上海艾力斯医药科技有限公司 一类具有部分PPARγ激动剂活性的化合物及其应用
US20100104640A1 (en) * 2007-04-17 2010-04-29 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
RU2345765C1 (ru) * 2007-07-09 2009-02-10 Илья Николаевич Медведев Способ коррекции гиперфибриногенемии при метаболическом синдроме
RU2339375C1 (ru) * 2007-07-09 2008-11-27 Илья Николаевич Медведев Способ коррекции вазопатии при метаболическом синдроме
RU2344818C1 (ru) * 2007-07-09 2009-01-27 Илья Николаевич Медведев СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2-АНТИПЛАЗМИНА ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ
RU2345767C1 (ru) * 2007-07-09 2009-02-10 Илья Николаевич Медведев Способ быстрой нормализации эндотелиоцитемии при метаболическом синдроме
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
RU2387449C1 (ru) * 2008-08-05 2010-04-27 Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию Способ лечения гипертензивных внутримозговых кровоизлияний
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN101869567A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 含有双胍类降糖药物和沙坦类降压药物的药物组合物及其用途
SG176585A1 (en) 2009-05-20 2012-01-30 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution
KR101069166B1 (ko) * 2009-06-02 2011-09-30 한국화학연구원 이미다조 페닐테트라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
RU2423126C1 (ru) * 2010-02-15 2011-07-10 Илья Николаевич Медведев Способ коррекции функций стенки сосудов у больных артериальной гипертонией i-ii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза
RU2423125C1 (ru) * 2010-02-15 2011-07-10 Илья Николаевич Медведев Способ нивелирования дисфункций сосудистой стенки у больных артериальной гипертонией iii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза
RU2422141C1 (ru) * 2010-02-15 2011-06-27 Илья Николаевич Медведев Способ нормализации функциональной активности стенки сосудов у больных артериальной гипертонией i-ii степени при метаболическом синдроме, перенесших тромбоз сосудов глаза
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
PT2640371T (pt) * 2010-11-15 2020-04-17 Boehringer Ingelheim Int Terapia antidiabética vasoprotetora e cardioprotetora
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
RU2699508C1 (ru) * 2018-07-25 2019-09-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения больных метаболическим синдромом
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
CN114073697B (zh) * 2021-01-19 2023-01-24 复旦大学附属肿瘤医院 Bcat2抑制剂在制备预防和/或治疗bcat2介导的相关代谢疾病药物中的用途
CN114786683B (zh) 2021-04-09 2024-01-12 北京大学 一种siRNA、药物组合物以及使用其治疗糖尿病的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265847A (en) * 1978-03-30 1981-05-05 Kirby Pharmaceuticals Ltd Tabletting process
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122010000024I1 (de) 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
PT97078B (pt) 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0636027B1 (en) 1992-04-13 1999-07-07 Zeneca Limited Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5824696A (en) 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
JP3883205B2 (ja) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
CN1192696A (zh) * 1995-06-07 1998-09-09 G·D·瑟尔公司 用于充血性心力衰竭治疗的螺甾内酯与血管紧张素ⅱ拮抗药组合疗法
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
ES2289814T3 (es) * 1998-07-10 2008-02-01 Novartis Pharma Ag Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
WO2000066161A1 (en) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
CA2405793A1 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
US6784207B2 (en) * 2000-08-04 2004-08-31 Roche Vitamins Inc. Phytanic acid derivative compositions
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
JP2003113120A (ja) * 2001-08-03 2003-04-18 Takeda Chem Ind Ltd 徐放性医薬
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20050004193A1 (en) * 2003-01-16 2005-01-06 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation

Also Published As

Publication number Publication date
MEP51108A (en) 2011-02-10
EA200600161A1 (ru) 2006-08-25
EA200900929A1 (ru) 2010-04-30
JP2007500677A (ja) 2007-01-18
US20050070594A1 (en) 2005-03-31
IL172693A (en) 2012-10-31
WO2005011680A1 (de) 2005-02-10
NO335444B1 (no) 2014-12-15
AU2004260606B2 (en) 2010-12-09
ZA200509835B (en) 2006-11-29
DK2119441T3 (en) 2015-08-10
EP1651213B1 (de) 2009-09-23
PT1651213E (pt) 2009-10-15
DK1651213T3 (da) 2010-02-01
EP1651213A1 (de) 2006-05-03
DK1651213T4 (da) 2013-04-15
DE10356815A1 (de) 2005-07-07
CN1829511B (zh) 2011-08-17
ES2334136T5 (es) 2013-05-21
CY1109560T1 (el) 2014-08-13
BRPI0413165A (pt) 2006-10-03
CN1829511A (zh) 2006-09-06
UA83854C2 (uk) 2008-08-26
JP4833840B2 (ja) 2011-12-07
EP2263670A1 (de) 2010-12-22
CN102139110A (zh) 2011-08-03
EP2263670B1 (de) 2015-09-09
ES2334136T3 (es) 2010-03-05
SI1651213T2 (sl) 2013-04-30
DE10346260A1 (de) 2005-04-28
EP2119441B1 (de) 2015-05-20
SI1651213T1 (sl) 2010-01-29
RS20060066A (sr) 2008-08-07
EA012600B1 (ru) 2009-10-30
CA2534006A1 (en) 2005-02-10
ATE443519T1 (de) 2009-10-15
EP1651213B2 (de) 2013-01-23
EA017640B1 (ru) 2013-02-28
HK1093305A1 (en) 2007-03-02
CN101926997A (zh) 2010-12-29
NO20060938L (no) 2006-02-27
IL172693A0 (en) 2006-04-10
DE10335027A1 (de) 2005-02-17
NZ544877A (en) 2009-04-30
KR20060054404A (ko) 2006-05-22
WO2005011680A8 (de) 2009-07-16
MXPA06001322A (es) 2006-05-04
ES2543722T3 (es) 2015-08-21
CA2534006C (en) 2010-07-13
DE502004010117D1 (de) 2009-11-05
PL1651213T5 (pl) 2013-04-30
HUE027274T2 (en) 2016-10-28
PL2119441T3 (pl) 2015-10-30
PL1651213T3 (pl) 2010-03-31
AU2004260606A1 (en) 2005-02-10
RS50793B (sr) 2010-08-31
EP2119441A1 (de) 2009-11-18

Similar Documents

Publication Publication Date Title
NO20060938L (no) Anvendelse av angiotensin II reseptor antagonister, spesielt telmisartan for a oke insulin sensitiviteten
Sica et al. Blood pressure–lowering efficacy of the fixed‐dose combination of azilsartan medoxomil and chlorthalidone: a factorial study
SE0202803D0 (sv) Implantable medical device
PT1925303E (pt) Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes
TR200102229T2 (tr) 3-Hidroksi-2-metilglutaril koenzim A redüktaz inhibitörlerinin diyabetik retinopati tedavisine yönelik bir ilacın imalatında kullanımı.
WO2008018050A3 (en) A device for use with reflective pulse oximetry
NO20072325L (no) Kombinasjonsterapi omfattende telmisartan og hydroklortiazid
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
WO2004075856A3 (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
Weir et al. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed‐dose combination in hypertensive patients with and without high cardiovascular risk
Black et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double‐blind study
Deedwania et al. Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status
CL2008000684A1 (es) Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CL2008002555A1 (es) Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia.
CO5560583A2 (es) Composiciones medicinales que comprenden antagonistas del receptor de angiotensina ii
Bansal et al. Fixed drug eruption due to cross reaction between two azoles used for different indications
Hansson Hypertension control for a new era: emerging differences among AIIRAs
ATE453396T1 (de) Kombinationspräparat aus einem thiaziddiuretikum und einem schleifendiuretikum
Morozova et al. Possibilities ARB II (sartans) in hypertensive patients
WO2003080118A3 (en) Combination of an aldosterone receptor antagonist and a fibric acid derivative